Advanced Oncotherapy PLC Update re admission of Subscription Shares (2255M)
September 20 2021 - 01:00AM
UK Regulatory
TIDMAVO
RNS Number : 2255M
Advanced Oncotherapy PLC
20 September 2021
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Update re admission of Subscription Shares
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces that further to its announcement of 3 September 2021,
application has been made for the 82,383,761 Subscription Shares
and 6,470,880 new ordinary shares in respect of the fee
arrangements set out in the Company's announcement of 11 August
2021 to be admitted to trading on AIM ("First Admission").
First Admission will take place on or around 24 September 2021.
The Company also announces that admission of the remaining
11,145,405 Subscription Shares will occur on or around 22 October
2021 ("Second Admission").
Upon First Admission, the Company's enlarged issued share
capital will comprise 439,189,371 Ordinary Shares, with voting
rights. The Company does not hold any Ordinary Shares in treasury.
Therefore, the total number of Ordinary Shares in the Company with
voting rights on First Admission will be 439,189,371. Upon Second
Admission, the Company's enlarged issued share capital will
comprise 450,334,776 Ordinary Shares, with voting rights. The
Company does not hold any Ordinary Shares in treasury. Therefore,
the total number of Ordinary Shares in the Company with voting
rights on Second Admission will be 450,334,776. The aforementioned
figures may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change in their
interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Defined terms used in this announcement shall have the same
meaning as in the announcement of 11 August 2021 unless otherwise
defined herein.
- ENDS -
Notes for editors
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Tel: +44 (0) 20 3328 5656
Amrit Nahal / Matt Butlin (Sales and Corporate Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR & IR) advancedoncotherapy@fticonsulting.com
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKCBKFBKDPCD
(END) Dow Jones Newswires
September 20, 2021 02:00 ET (06:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2023 to Mar 2024